MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced the in-licensing of a next-generation selective ...
IMP-1734 is under development for the treatment of solid tumors, metastatic breast cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer and metastatic castrate resistant prostate ...
Pancreatic cancer is a highly lethal digestive malignancy with a 5-year survival rate of 10%. So far, the available therapeutic strategies are scarce and the few advancements made, as is the case of ...